Log In
BCIQ
Print this Print this
 

brodalumab (KHK4827) (formerly AMG 827)

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman IgG2 mAb against IL-17 receptor (IL17R; IL17RA)
Molecular Target Interleukin-17 (IL-17) receptor (IL17R) (IL17RA)
Mechanism of ActionAntibody; Interleukin-17 (IL-17) receptor agonist
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$445.0M

$150.0M

$345.0M


 Deals Details
Get a free BioCentury trial today